3 Anti-Infective and Gastro Franchise, Latin America Branded Generics and Respiratory Leader Stocks With a Strong Future Roadmap: Alkem Laboratories, Caplin Point Laboratories and Cipla
- October 23, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Alkem Laboratories, Caplin Point Laboratories and Cipla: ROE of 11.3% to 17.9% and FY22 to FY26 revenue CAGR of 7.1% to 15.2%. Prices as of 22 Oct 2026.
Quick Answer
The three branded pharma and emerging market stocks to watch are Alkem Laboratories, Caplin Point Laboratories and Cipla. Their return on equity ranges from 11.3% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 15.2%. Caplin Point Laboratories leads on both return on equity at 17.9% and revenue growth at 15.2% a year. Prices are based on the 22 October 2026 close, and this article is educational, not investment advice.
Branded pharma and emerging market stocks let investors follow companies that sell trusted medicines across many markets. Alkem Laboratories, Caplin Point Laboratories and Cipla cover an anti-infective and gastro franchise, Latin America branded generics and a respiratory medicines leader.
This list covers three branded pharma and emerging market stocks with complete current figures: Alkem Laboratories, Caplin Point Laboratories and Cipla. Every figure comes from the latest reported financials and the 22 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Branded Pharma and Emerging Market Stocks?
Branded pharma and emerging market stocks are listed pharmaceutical companies that sell prescription brands in India and in emerging markets. Their earnings depend on brand strength, doctor reach and market share.
Branded Pharma and Emerging Market Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Alkem Laboratories | 5,015 | 59,723 | 27.1 | 36.0 | 16.7 | 0.15 |
| Caplin Point Laboratories | 2,221.6 | 17,194 | 25.4 | 36.0 | 17.9 | 0.00 |
| Cipla | 1,330.9 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing branded pharma and emerging market stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Branded Pharma and Emerging Market Stocks Have a Strong Roadmap in India?
Branded pharma and emerging market stocks have a strong roadmap in India because rising incomes and wider insurance cover lift demand for chronic and acute care medicines at home and abroad.
- Brand trust. Doctor-preferred brands hold share in key therapies.
- Emerging markets. Branded generics grow in Latin America and Africa.
- Respiratory demand. Inhalers and chronic care medicines see steady growth.
Why Alkem Laboratories Features Among These Branded Pharma and Emerging Market Stocks
Among the branded pharma and emerging market stocks on this list, Alkem Laboratories is a Mumbai-based pharmaceutical company with a leading domestic franchise in anti-infectives, gastro-intestinal, pain and vitamins, along with exports of generics and a contract manufacturing and active ingredient business.
Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%.
In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0.
Roadmap: Alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
What to watch: Check the growth in chronic therapies in India and the contribution from the international and contract manufacturing businesses.
Why Caplin Point Laboratories Features Among These Branded Pharma and Emerging Market Stocks
Among the prescription brand company shares on this list, Caplin Point Laboratories, based in Chennai, sells branded generic medicines in Latin America and other emerging markets and has built a regulated-market business through its sterile injectables arm.
In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%.
Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0.
Roadmap: The company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
What to watch: Follow new US product approvals and currency trends in Latin American markets.
Why Cipla Features Among These Branded Pharma and Emerging Market Stocks
Among the three companies on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Alkem Laboratories vs Caplin Point Laboratories vs Cipla on Key Financials
The table below sets the three branded pharma and emerging market stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Alkem Laboratories | 10,797 | 15,296 | 9.1% | 2,353 | 15.4% |
| Caplin Point Laboratories | 1,308 | 2,303 | 15.2% | 650 | 28.2% |
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
Caplin Point Laboratories posts the highest return on equity in this group at 17.9%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Caplin Point Laboratories shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with branded pharma and emerging market stocks is to check each new quarterly result against the capacity plans the company described earlier.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Alkem Laboratories | 3,508 | 3,893 | 11.0% |
| Caplin Point Laboratories | 533 | 644 | 20.7% |
| Cipla | 7,216 | 7,330 | 1.6% |
Key Risks to Check Before Investing in Branded Pharma and Emerging Market Stocks
Every theme carries risks that deserve a check before any decision. For these branded pharma and emerging market stocks, the main points are: Long-term prescription brand company shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Price controls. Government limits on listed medicines can cap realisations.
- Currency moves. Export earnings are affected by exchange rates.
- Regulatory checks. Plant inspections need constant readiness.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter branded pharma and emerging market stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Branded Pharma and Emerging Market Stocks
Branded pharma and emerging market stocks reward investors who follow brand strength, doctor reach and exports together. Alkem Laboratories, Caplin Point Laboratories and Cipla each have room to widen their reach. Based on the 22 October 2026 close, Alkem Laboratories trades at Rs 5,015, Caplin Point Laboratories at Rs 2,221.6 and Cipla at Rs 1,330.9. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these branded pharma and emerging market stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track branded pharma and emerging market stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are branded pharma and emerging market stocks?
Ans. Branded pharma and emerging market stocks are listed pharmaceutical companies that sell prescription brands in India and in emerging markets. Their earnings depend on brand strength, doctor reach and market share. This list looks at three of them, Alkem Laboratories, Caplin Point Laboratories and Cipla, using reported FY22 to FY26 financials and the 22 October 2026 closing prices.
Which branded pharma and emerging market stocks are covered in this list?
Ans. This list covers Alkem Laboratories, Caplin Point Laboratories and Cipla. Based on the 22 October 2026 close, Alkem Laboratories traded at Rs 5,015, Caplin Point Laboratories at Rs 2,221.6 and Cipla at Rs 1,330.9. Their return on equity ranges from 11.3% to 17.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 15.2%.
Why do branded pharma and emerging market stocks have a strong future roadmap in India?
Ans. Branded pharma and emerging market stocks have a strong roadmap in India because rising incomes and wider insurance cover lift demand for chronic and acute care medicines at home and abroad. The main drivers are as follows. Brand trust. Doctor-preferred brands hold share in key therapies. Emerging markets. Branded generics grow in Latin America and Africa. Respiratory demand. Inhalers and chronic care medicines see steady growth. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Alkem Laboratories performed financially?
Ans. Revenue rose from Rs 10,797 crore in FY22 to Rs 15,296 crore in FY26, a compound annual growth rate of 9.1%. Net profit grew from Rs 1,680 crore in FY22 to Rs 2,353 crore in FY26, which works out to a compound annual growth rate of 8.8%. In the June 2026 quarter, revenue grew 11.0% year on year to Rs 3,893 crore. The company has a return on equity of 16.7%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 59,723 crore. The stock trades at a P/E of 27.1, below the industry P/E of 36.0. Looking ahead, alkem’s strong domestic brands and wide medical representative network support steady growth, while its international business adds regulated market exposure. The company is also building its chronic and specialty portfolio and its biosimilars pipeline.
How has Caplin Point Laboratories performed financially?
Ans. Revenue rose from Rs 1,308 crore in FY22 to Rs 2,303 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 308 crore in FY22 to Rs 650 crore in FY26, which works out to a compound annual growth rate of 20.5%. In the June 2026 quarter, revenue grew 20.7% year on year to Rs 644 crore, while net profit rose 18.8% to Rs 179 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 17,194 crore. The stock trades at a P/E of 25.4, below the industry P/E of 36.0. Looking ahead, the company combines a high-return emerging-market distribution model with a growing US injectables portfolio. New approvals from its sterile facilities and expansion of its local distribution reach support the next leg of growth.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What risks should investors check before buying branded pharma and emerging market stocks?
Ans. Investors should check a few risks before buying branded pharma and emerging market stocks. Price controls. Government limits on listed medicines can cap realisations. Currency moves. Export earnings are affected by exchange rates. Regulatory checks. Plant inspections need constant readiness. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of branded pharma and emerging market stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 22 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.